Bringing together gynecological researchers from Washington, Oregon & British Columbia
PROGRAM

8:00am – 8:30am  Check-in & Poster Set-up

8:30am – 8:40am  Opening Remarks by Kiran Dhillon, PhD, Rivkin Center

SESSION I: DETECTION AND PREVENTION

Moderator  Rosana Risques, PhD (2017 Pape Family Pilot Study Award; 2019 Rivkin Bridge Funding Award)

8:40am – 8:55am  Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian cancer
Rosana Risques, PhD, University of Washington

8:55am – 9:10am  The effect of OCP use on the incidence of pre-cancerous p53 lesions in fallopian tube fimbria
Kendall Greening, MSc, BC Cancer Research Centre

9:10am – 9:25am  Clinical tissue proteomics identifies new mesonephric carcinoma biomarkers
Evan Gibbard, University of British Columbia

9:25am – 9:40am  Ethnic disparity in detection of ovarian malignancy
Charles Dunton, MD, ASPiRA Labs

9:40am – 10:10am  Coffee Break

SESSION II: CANCER MECHANISMS

Moderator  Bo Yu, MD (2017 Cookie Laughlin Bridge Funding Award)

10:10am – 10:25am  Modelling initiation events of low-grade serous ovarian cancers with organoid cultures and single cell sequencing
Joyce Zhang, BC Cancer Research Centre

10:25am – 10:40am  Targeted next-generation sequencing identifies mutations in epigenetic regulators in a large cohort of adult-type granulosa cell tumors
Jessica Pilsworth, University of British Columbia

10:40am – 10:55am  Single cell RNA sequencing of normal endometrial organoids reveals prognostic markers in gynecologic tumors
Dawn Cochrane, PhD, BC Cancer Research Centre

10:55am – 11:00am  Keynote Introduction by Mark Carey, MD

11:00am – 12:00pm  Keynote Address
Defining the trajectory of ovarian cancer from early tubal precursors
Ronny Drapkin, MD/PhD, University of Pennsylvania

12:00pm – 1:00pm  Lunch (provided)

12:00pm – 1:00pm  Trainee Lunch with Keynote Speaker
SESSION III: MANAGEMENT AND RESOURCES

Moderator
Robyn Andersen, PhD (2017 Pilot Study Award)

1:00pm – 1:15pm
*Piloting a meditation intervention for ovarian cancer survivors to change Heart Rate Variability (HRV)*
Robyn Andersen, PhD, Fred Hutchinson Cancer Research Center

1:15pm – 1:30pm
*Quality improvement assessment of a standardized multidisciplinary approach to prescribing PARP inhibitors*
Amy Indorf, PharmD, University of Washington/Seattle Cancer Care Alliance

1:30pm – 1:45pm
*Improving findability of gynecological biospecimens and associated data through the Cascadia Data Discovery Initiative*
Brenda Kostelecky, PhD, Cascadia Data Alliance at Fred Hutch

1:45pm – 2:10pm
*Poster Presentation Lightning Round*

2:10pm – 2:40pm
*Coffee Break*

SESSION IV: THERAPEUTICS

Moderator
Andre Lieber, MD/PhD (2010 Pilot Study Award; 2016 Lester and Bernice Smith Challenge Grant)

2:40pm – 2:55pm
*Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models*
Andre Lieber, MD/PhD, University of Washington

2:55pm – 3:10pm
*Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors*
Kristin Anderson, PhD, Fred Hutchinson Cancer Research Center

3:10pm – 3:25pm
*The immune and tumor metabolic ecosystem in human ovarian cancer*
Julian Lum, PhD, BC Cancer Research Centre

3:25pm – 3:40pm
*Inflammatory response in endometrial carcinoma is associated with tumor phenotype and host exposures in the Nurses’ Health Study*
T. Rinda Soong, MD/PhD, University of Washington

3:40pm – 3:45pm
*Closing Remarks by Nora Disis, MD*

SESSION V: POSTER SESSION

3:45pm – 5:00pm
*Poster Session*

5:00pm – 6:30pm
*RECEPTION*
POSTERS

A CLIA certified functional precision medicine assay, the PARIS© test, to predict drug response for ovarian cancer
Carla Grandori, MD/PhD, SEEngine Precision Medicine

Single-cell sequencing to investigate the cellular origins of endometrium-derived ovarian carcinomas
Germain C. Ho, BC Cancer Research Centre

CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines
Joshua Hoenisch, University of British Columbia

Potential for vitamin D in the prevention of ovarian cancer in women with BRCA1 mutations
Sonali Joshi, PhD, Oregon Health and Science University

Single cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor
Marilyne Labrie, PhD, Oregon Health and Science University

Targeting FANCD2 increases chemosensitivity of ovarian cancer cells
Tanja Pejovic, MD/PhD, Knight Cancer Institute / Oregon Health and Science University

Selective killing of SMARCA4-deficient ovarian cancer by mitochondria respiration inhibitors
Yemin Wang, PhD, BC Cancer Research Centre

Microbiome profiling of fallopian tubes
Bo Yu, MD, University of Washington

PLANNING COMMITTEE

Mark Carey, MD, University of British Columbia
Kiran Dhillon, PhD, Rivkin Center for Ovarian Cancer
Nora Disis, MD, University of Washington / Fred Hutch
Jackie Lang, PhD, Rivkin Center for Ovarian Cancer
Gordon Mills, MD/PhD, Oregon Health and Science University

SPONSORS

TBA